Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumococcal Vaccination and Revaccination in CLL
NCT05316831Phase 4Completed
- Sponsor
- Region Örebro län
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal infection (4 arms), sponsored by Region Örebro län. Primary endpoints: Immune response 3-5 years after primary vaccination and Change in immune response after revaccination at 52 weeks. Started Jan 2019; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05316831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316831.